Here an overview of the topics covered:
IMI2 – Call 11
- One
topic on ‘Exploitation of IMI project results’
Deadline for submission of proposals: 24 October 2017
More information on the topics, their conditions
and key dates can be found here.
IMI2 – Call 12
- Topic
1: Development and validation of technology enabled, quantitative and
sensitive measures of functional decline in people with early stage
Alzheimer’s disease (RADAR-AD)
- Topic
2: FAIRification of IMI and EFPIA data
- Topic
3: Development of sensitive and validated clinical endpoints in primary
Sjögren’s Syndrome (pSS)
- Topic
4: European Health Data Network (EHDN)
- Topic
5: Analysing the infectious disease burden and the use of vaccines to
improve healthy years in aging populations
- Topic
6: Discovery and characterisation of blood-brain barrier targets and
transport mechanisms for brain delivery of therapeutics to treat
neurodegenerative & metabolic diseases
- Topic
7: European Screening Centre: unique library for attractive biology
(ESCulab)
Deadline for submission of proposals: 24 October 2017
More information
on the topics, their conditions and key dates can be found here.
Background
- IMI
is a partnership between the European Union and the European
pharmaceutical industry, represented by the European Federation of
Pharmaceutical Industries and Associations (EFPIA).
- Through
the IMI 2 programme, IMI has a budget of €3.3 billion for the period
2014-2024. Half of this comes from the EU’s research and innovation
programme, Horizon 2020. The other half comes from large companies, mostly
from the pharmaceutical sector; these do not receive any EU funding, but
contribute to the projects ‘in kind’, for example by donating their
researchers’ time or providing access to research facilities or resources.
